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Introduction
============

Possible cardioprotective effects of alcohol consumption seen in observational studies continue to be hotly debated in the medical literature and popular media. In the absence of clinical trials, clinicians must interpret these data when answering patients' questions about taking alcohol to reduce their risk of cardiovascular disease. Systematic reviews and meta-analyses have addressed the association of alcohol consumption with cardiovascular disease outcomes[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] but have not uniformly addressed associations between alcohol use and mortality from cardiovascular disease, as well as the incidence and mortality from coronary heart disease and stroke. Additionally, further studies have been published since 2006, when the most recent reviews appeared. The continuing debate on this subject warrants an in depth reassessment of the evidence.

In this paper, we synthesise results from longitudinal cohort studies comparing alcohol drinkers with non-drinkers for the outcomes of overall mortality from cardiovascular disease, incident coronary heart disease, mortality from coronary heart disease, incident stroke, and mortality from stroke. Because of the many biological effects of alcohol consumption, we also examine the association of alcohol with mortality from all causes when this is reported in studies. We conducted meta-analyses for each of these outcomes and a sensitivity analysis with lifetime abstainers as the reference category to account for the heterogeneity within the reference group of non-drinkers. We also examined the effect of confounding on the strength of observed associations. In our companion paper,[@ref110] we link these cardiovascular outcomes with experimental trials of alcohol consumption on candidate causal molecular markers.

Methods
=======

Data sources and searches
-------------------------

We performed a systematic review and meta-analysis following a predetermined protocol in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines.[@ref9] We identified all potentially relevant articles regardless of language by searching Medline (1950 through September 2009) and Embase (1980 through September 2009). Searches were enhanced by scanning bibliographies of identified articles and review articles, as well as reviewing conference proceedings from three major scientific meetings (American Heart Association, American College of Cardiology, and European Heart Congress) between 2007 and 2009. Experts in the field were contacted regarding missed, ongoing, or unpublished studies.

To search electronic databases, we used the strategy recommended for systematic reviews of observational studies.[@ref10] We specified three comprehensive search themes:

-   To identify relevant terms related to the exposure of interest (theme 1), the first Boolean search used the term "or" to explode (search by subject heading) and map (search by keyword) the medical subject headings "ethanol" or "alcohol" or "alcoholic beverages" or "drinking behaviour" or "alcohol drinking" or text words "drink\$" or "liquor\$" or "ethanol intake" or "alcohol\$ drink\$" or "ethanol drink\$"

-   To identify relevant outcomes (theme 2), a second Boolean search was performed using the term "or" to explode and map the medical subject headings "stroke" or "cardiovascular diseases" or "myocardial infarction" or "myocardial ischemia" or "coronary artery disease" or "heart infarction" or text words "cva\$" or "infarct\$" or "ischem\$" or "cvd" or "ami" or "ihd" or "cad"

-   To identify relevant study designs (theme 3), a final Boolean search using the term "or" to explode and map the medical subject headings "cohort studies" or "follow-up studies" or "incidence" or "prognosis" or "early diagnosis" or "survival analysis" or text words "course" or predict\$" or "prognos\$" was performed.

These three comprehensive search themes were then combined using the Boolean operator "and" in varying combinations.

Study selection
---------------

Two individuals (SEB and PER) independently reviewed all identified abstracts for eligibility. All abstracts reporting on the association between alcohol intake and cardiovascular disease events were selected for full text review. This stage was intentionally liberal. We discarded only those abstracts that clearly did not meet the aforementioned criteria. The inter-rater agreement for this review was high (κ=0.86 (95% confidence interval 0.80 to 0.91)). Disagreements were resolved by consensus.

The same reviewers performed the full text review of articles that met the inclusion criteria and articles with uncertain eligibility. Articles were retained if they met the inclusion criteria for study design (prospective cohort design), study population (adults ≥18 years old without pre-existing cardiovascular disease), exposure (current alcohol use with a comparison group of non-drinkers), and outcome (overall cardiovascular disease mortality or atherothrombotic conditions, specifically incident coronary heart disease, coronary heart disease mortality, incident stroke, or stroke mortality). Both published and unpublished studies were eligible for inclusion. Authors were contacted if the risk profile of the cohort was unclear.

Data extraction and quality assessment
--------------------------------------

The primary exposure variable was the presence of active alcohol drinking at baseline compared with a reference group of non-drinkers. Because of the heterogeneity of this reference group, we identified the subset of studies using lifetime abstainers as the reference group and studies that distinguished former drinkers from non-drinkers. Whenever available, we extracted information on amount of alcohol consumed, using grams of alcohol per day as the common unit of measure. When a study did not specifically report the grams of alcohol per unit, we used 12.5 g/drink for analysis.[@ref11] We standardised portions as a 12 oz (355 ml) bottle or can of beer, a 5 oz (148 ml) glass of wine, and 1.5 oz (44 ml) glass of 80 proof (40% alcohol) distilled spirits. Volume of intake was categorised as \<2.5 g/day (\<0.5 drink), 2.5--14.9 g/day (about 0.5--1 drink), 15--29.9 g/day (about 1--2.5 drinks), 30--60 g/day (about 2.5--5 drinks), and \>60 g/day (≥5 drinks).

The outcome variables of interest were defined as the presence or absence of death from cardiovascular disease (that is, fatal cardiovascular or stroke events), incident coronary heart disease (fatal or non-fatal incident myocardial infarction, angina, ischaemic heart disease, or coronary revascularisation), death from coronary heart disease (fatal myocardial infarction or ischaemic heart disease), incident stroke (ischaemic or haemorrhagic events), or death from stroke. A secondary analysis was performed within these selected studies to determine the association between alcohol consumption and the risk of death from all causes.

Both reviewers independently extracted data from all studies fulfilling the inclusion criteria, and any disagreement was resolved by consensus. We extracted the data elements of cohort name, sample size, and population demographics (country, percentage male, mean age or age range). We also extracted information for key indicators of study quality in observational studies proposed by Egger et al[@ref10] and Laupacis et al.[@ref12] Specifically, we evaluated the effect on each outcome of the number of potential confounding variables and the number of years participants were followed.

Data synthesis and analysis
---------------------------

The relative risk was used as the common measure of association across studies. Hazard ratios and incidence density ratios were directly considered as relative risks. Where necessary, odds ratios were transformed into relative risks with this formula:

1.  Relative risk=odds ratio/\[(1--P~o~)+(P~o~×odds ratio)\], in which P~o~ is the incidence of the outcome of interest in the non-exposed group.[@ref13]

The standard error of the resulting converted relative risk was then determined with this formula:

1.  SElog(relative risk)=SElog(odds ratio)×log(relative risk)/log(odds ratio).

Because these transformations can underestimate the variance of the relative risks derived from the odds ratios,[@ref14] [@ref15] we performed a sensitivity analysis that excluded four studies for which this transformation had been applied. All analyses were performed with Stata 10.0 (StataCorp, College Station TX, USA). The Stata "metan" command was used to pool the ln(relative risks) across studies according to the DerSimonian and Laird random effects model.[@ref16]

In some studies, a single relative risk (or odds ratio) was not available for drinkers versus non-drinkers because the data were presented as only a dose-response (that is, several alcohol consumption levels relative to non-drinkers). In these cases, we first pooled across levels of intake within the study using a random effects model to derive a single relative risk for drinkers versus non-drinkers. The resulting single, study-specific relative risk was then pooled with those of other studies.

To visually assess the relative risk estimates and corresponding 95% confidence intervals across studies, we generated forest plots sorted by year of publication. Analyses were stratified by study quality criteria and by participant characteristics.

To assess heterogeneity of relative risks across studies, we inspected forest plots and calculated Q (significance level of P≤0.10) and I^2^ statistics.[@ref17] [@ref18] In the presence of heterogeneity, random effects models were used (rather than fixed effects models) to obtain pooled effect estimates across studies. Sensitivity analyses and stratified analyses were performed to assess the associations of selected study quality and clinical factors on cardiovascular risk, including number of confounding factors and duration of follow-up dichotomised at the median value. We also performed a sensitivity analysis excluding studies reporting only odds ratios. We conducted a cumulative meta-analysis of studies ordered chronologically to assess the sequential contributions of studies published over time.[@ref19] Finally, we assessed evidence of publication bias through visual inspection of funnel plots and Begg's rank correlation test for asymmetry.[@ref20] [@ref21]

Results
=======

Identification of studies
-------------------------

Our initial search yielded a total of 4235 unique citations (fig 1[](#fig1){ref-type="fig"}). After two rounds of reviews and searching citations of retained articles, we identified 131 studies as potentially relevant for analysis. We excluded studies of cardiovascular outcomes predefined as ineligible (such as chronic congestive heart failure or stable angina), non-atherothrombotic end points (such as arrhythmias), composite end points, or non-cardiovascular outcomes (such as cancer), and duplicate reports. This left 84 studies for our systematic review and meta-analysis. Table 1[](#tbl1){ref-type="table"} provides details of the included studies.[@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] [@ref71] [@ref72] [@ref73] [@ref74] [@ref75] [@ref76] [@ref77] [@ref78] [@ref79] [@ref80] [@ref81] [@ref82] [@ref83] [@ref84] [@ref85] [@ref86] [@ref87] [@ref88] [@ref89] [@ref90] [@ref91] [@ref92] [@ref93] [@ref94] [@ref95] [@ref96] [@ref97] [@ref98] [@ref99] [@ref100] [@ref101] [@ref102] [@ref103] [@ref104] [@ref105] Of these 84 studies, 34 (40%) reported on all-male cohorts, six (7%) reported on women only, and 44 (52%) included both men and women.

![**Fig 1** Details of study selection for review](ronp804823.f1_default){#fig1}

###### 

 Details of studies included in meta-analysis of association of alcohol consumption with selected cardiovascular disease outcomes

  Study                                  Cohort designation                                                 No of subjects   Country                 Men (%)      Age range (years)   Study follow-up (years)               Outcomes measured
  -------------------------------------- ------------------------------------------------------------------ ---------------- ----------------------- ------------ ------------------- ------------------------------------- --------------------------------------
  Albert et al 1999^22^                  Physicians' Health Study                                           21 537           USA                     100          40--84              12                                    CHD mortality
  Bazzano et al 2007^23^                 China National Hypertension Survey Epidemiology Follow-up Study    64 338           China                   100          ≥40                 8                                     Incident stroke and stroke mortality
  Bazzano et al 2009^24^                 64 597                                                             China            100                     ≥40          8                   Incident CHD; CVD and CHD mortality   
  Berberian et al 1994^25^               Zoetermeer Cohort                                                  1620             Netherlands             46.9         \>20                10                                    CVD mortality
  Berger et al 1999^26^                  Physicians' Health Study                                           22 071           USA                     100          40--84              12.2                                  Incident stroke
  Blackwelder et al 1980^27^             Honolulu Heart Program                                             7888             USA                     100          Not reported        8                                     CHD and stroke mortality
  Boffetta et al 1990^28^                American Cancer Society Prospective Study                          276 802          USA                     100          40--59              12                                    CHD mortality
  Burke et al 2007^29^                   Western Australian Aboriginal cohort                               514              Australia               50.2         15--88              11.6                                  Incident CHD
  Camargo et al 1997^30^                 Physicians' Health Study                                           22 071           USA                     100          40--84              11                                    Incident CHD
  Chiuve et al 2008^31^                  Nurses' Health Study                                               71 243           USA                     0            34--59              20                                    Incident stroke
  Health Professionals Follow-up Study   43 685                                                             USA              100                     40--75       18                  Incident stroke                       
  Colditz et al 1985^32^                 Massachusetts cohort                                               1184             USA                     38           ≥66                 4.75                                  CHD mortality
  Cullen et al 1993^33^                  Brusselton, Western Australian cohort                              2171             Australia               50           ≥40                 23                                    CHD and CVD mortality
  Deev et al 1998^34^                    US-Russian Lipid Research Clinics Prevalence Study                 4011             USA                     46.6         40--69              13                                    CVD mortality
  4153                                   Russia                                                             46.7             40--69                  13                                                                     
  Diem et al 2003^35^                    Multinational Study of Vascular Disease in Diabetes                287              Switzerland             56.4         ≥35                 12.6                                  CHD mortality
  Djousse et al 2002^36^                 Framingham Study                                                   9171             USA                     42.2         ≥50                 10                                    Incident stroke
  Djousse et al 2009^37^                 Women's Health Study                                               26 399           USA                     0            ≥45                 12                                    CVD mortality
  Doll et al 2005^38^                    British Physician Cohort                                           12 325           UK                      100          48--78              23                                    CHD mortality
  Donahue et al 1986^39^                 Honolulu Heart Program                                             8006             USA                     100          45--69              12                                    Incident stroke
  Ebbert et al 2005^40^                  Iowa Women's Health Study                                          30 518           USA                     0            55--69              14                                    CHD mortality
  Ebrahim et al 2008^41^                 Women's Heart and Health Study                                     2717             UK                      0            60--79              4.7                                   Incident CHD
  Caerphilly Study                       1291                                                               UK               100                     47--67       20                                                        
  Elkind et al 2006^42^                  Northern Manhattan Study                                           3176             USA                     37.2         ≥40                 5.9                                   Incident stroke
  Friedman et al 1986^43^                Framingham Study                                                   4745             USA                     44.4         30--59              24                                    CHD mortality
  Fuchs et al 1995^44^                   Nurses' Health Study                                               85 709           USA                     0            34--59              12                                    CVD mortality
  Fuchs et al 2004^45^                   Atherosclerosis Risk in Communities Study                          14 506           USA                     43.3         45--64              9.8                                   Incident CHD
  Garfinkel et al 1988^46^               American Cancer Society Prospective Study                          581 321          USA                     0            \>30                12                                    CHD mortality
  Garg et al 1992^47^                    National Health and Nutrition Examination Study                    3718             USA                     0            45--74              13                                    CHD mortality
  Gaziano et al 2000^48^                 Physicians' Health Study                                           89 299           USA                     100          40--84              5.5                                   CVD and stroke mortality
  Gordon et al 1983^49^                  Framingham Study                                                   4625             USA                     43.8         29--62              22                                    Incident CHD
  Gordon et al 1985^50^                  Albany Study                                                       1755             USA                     100          38--55              18                                    Incident CHD
  Gronbaek et al 1995^51^                Copenhagen City Heart Study                                        13 285           Denmark                 45.5         30--79              12                                    CVD mortality
  Gun et al 2006^52^                     Employees of Australian Institute of Petroleum member companies    16 547           Australia               100          NR                  20                                    CHD mortality
  Hammar et al 1997^53^                  Swedish Twin Register                                              1900             Sweden                  67.4         30--74              NR                                    Incident CHD
  Hansagi et al 1995^54^                 Swedish Twin Register                                              15 077           Sweden                  47           ≥42                 20                                    Stroke mortality
  Harriss et al 2007^55^                 Melbourne Collaborative Cohort Study                               38 200           Australia               39.7         27--75              11.4                                  CHD and CVD mortality
  Hart et al 2008^56^                    Midspan Collaborative Cohort Study                                 6000             Scotland                100          35--64              35                                    CHD and stroke mortality
  Hein et al 1996^57^                    Copenhagen Male Study                                              2826             Denmark                 100          53--74              6                                     Incident CHD
  Ikehara et al 2009^58^                 Japan Public Health Center-Based Prospective Study                 19 356           Japan                   100          40--69              9.9                                   Incident CHD and stroke
  Iso et al 1995^59^                     Rural Japanese cohorts                                             2890             Japan                   100          40--69              10.5                                  Incident CHD and stroke
  Jakovljevic et al 2004^60^             Institute for Chronic Diseases and Gerontology                     286              Serbia and Montenegro   50.7         30--60              20                                    Stroke mortality
  Jamrozik et al 2000^61^                Perth Community Stroke Study                                       931              Australia               48           \>18                4                                     CVD mortality
  Jousilahti et al 2000^62^              Finnish Cohort                                                     14 874           Finland                 48.2         25--64              12                                    Incident stroke
  Kitamura et al 1998^63^                Japanese Male Employees                                            8476             Japan                   100          40--59              8.8                                   Incident CHD
  Kittner et al 1983^64^                 Puerto Rico Heart Health Program                                   9150             Puerto Rico             100          35--79              12                                    Incident CHD and CHD mortality
  Kivela et al 1989^65^                  Two Finnish cohorts from the Seven Countries Study                 1112             Finland                 100          55--74              10                                    CVD mortality
  Kiyohara et al 1995^66^                Hisayama Study                                                     1621             Japan                   43.6         ≥40                 26                                    Incident stroke
  Klatsky et al 1990^67^                 Kaiser Permanente Medical Care Program Cohort                      123 840          USA                     40.5         \<30--\>70          7                                     CVD mortality
  Klatsky et al 1997^68^                 128 934                                                            USA              44                      \<30--\>70   NR                  Incident CHD                          
  Klatsky et al 2002^69^                 128 934                                                            USA              44                      \<30--\>70   18                  Incident stroke                       
  Knoops et al 2004^70^                  Healthy Ageing: A Longitudinal Study in Europe                     2339             11 European countries   64.4         70--90              10                                    CHD and CVD mortality
  Kono et al 1986^71^                    Japanese Male Physician Cohort                                     5135             Japan                   100          NR                  19                                    CHD, CVD and stroke mortality
  Leppala et al 1999^72^                 Alpha-Tocopherol, Beta-Carotene Cancer Prevention cohort           26 556           Finland                 100          50--69              6.1                                   Incident stroke
  Lin et al 2005^73^                     Japan Collaborative Cohort Study for Evaluation of Cancer Risk     110 792          Japan                   41.9         40--79              11                                    CVD mortality
  Manttari et al 1997^74^                Helsinki Heart Study                                               1924             Finland                 100          40--55              5                                     Incident CHD
  Marques-Vidal et al 2004^75^           PRIME Study---France                                               7352             France                  100          50--59              5                                     Incident CHD
  PRIME Study---Northern Ireland         2398                                                               Ireland          100                     50--59       5                                                         
  Maskarinec et al 1998^76^              Multiethnic cohort (Hawaii)                                        27 678           USA                     50.1         \>30                NR                                    CHD and stroke mortality
  Mukamal et al 2003^77^                 Health Professionals Follow-up Study                               38 077           USA                     100          40--75              12                                    Incident CHD and CHD mortality
  Mukamal et al 2005^78^                 Cardiovascular Health Study                                        4410             USA                     36.1         ≥65                 9.2                                   Incident stroke
  Mukamal et al 2006^79^                 4410                                                               USA              38.7                    ≥65          9.2                 Incident CHD                          
  Murray et al 2002^80^                  Manitoba Health Cohort                                             1154             Canada                  50.2         18--64              8                                     Incident CHD
  Murray et al 2005^81^                  Lung Health Study                                                  3702             Canada                  100          35--60              14                                    Incident CHD
  Pedersen et al 2008^82^                Copenhagen City Heart Study                                        11 914           Denmark                 44.3         ≥20                 20                                    CHD mortality
  Rehm et al 1997^83^                    National Health and Nutrition Examination Study                    6788             USA                     43.6         40--75              14.6                                  Incident CHD and CHD mortality
  Renaud et al 1999^84^                  Cohort from Centre de Medecine Preventive                          36 250           France                  100          40--60              12--18                                CHD and CVD mortality
  Salonen et al 1983^85^                 Two counties of eastern Finland                                    4063             Finland                 100          30--59              7                                     Incident CHD
  Sankai et al 2000^86^                  Six Japanese communities                                           12 372           Japan                   40.2         40--69              9.4                                   Incident stroke
  Scherr et al 1992^87^                  Established populations for Epidemiologic Studies of the Elderly   6891             USA                     36.9         \>65                5                                     CVD mortality
  Shaper et al 1987^88^                  British Regional Heart Study                                       6103             UK                      100          40--59              6.2                                   Incident CHD
  Simons et al 1996^89^                  Dubbo Cohort of New South Wales                                    2805             Australia               44.1         ≥60                 6.4                                   Incident CHD
  Solomon et al 2000^90^                 Nurses' Health Study                                               121 700          USA                     0            30--55              NR                                    Incident CHD and CHD mortality
  Suh et al 1992^91^                     Multiple Risk Factor Intervention Trial                            11 688           USA                     100          35--57              3.8                                   CHD mortality
  Suhonen et al 1987^92^                 Social Insurance Institution's Mobile Clinic Health Survey         4532             Finland                 100          40--64              5                                     CHD mortality
  Thun et al 1997^93^                    Cancer Prevention Study II                                         489 626          USA                     51.3         30--104             9                                     CHD, CVD and stroke mortality
  Tolstrup et al 2006^94^                Danish Cohort                                                      53 500           Denmark                 46.8         50--65              5.7                                   Incident CHD
  Trevisan et al 2001^95^                Risk Factors and Life Expectancy Study                             8647             Italy                   100          30--59              7                                     CHD and CVD mortality
  Truelsen et al 1998^96^                Copenhagen City Heart Study                                        13 329           Denmark                 45.5         45--84              16                                    Incident stroke
  Valmadrid et al 1999^97^               Wisconsin Epidemiologic Study of Diabetic Retinopathy              983              USA                     45.2         NR                  12.3                                  CHD mortality
  Waskiewicz et al 2004^98^              Pol-MONICA Programme                                               5452             Poland                  49.3         35--64              NR                                    CVD mortality
  Wellmann et al 2004^99^                MONICA Augsburg Cohort                                             2710             Germany                 49.6         35--64              10                                    Incident CHD
  Wilkins 2002^100^                      National Population Health Survey                                  6014             Canada                  43.8         ≥40                 4                                     Incident CHD
  Woo et al 1990^101^                    Elderly Chinese Cohort                                             427              China                   40           ≥60                 2.5                                   Incident stroke
  Xu et al 2007^102^                     Husbands from Shanghai Women's Health Study                        64 515           China                   100          30--89              4.6                                   CHD and CVD mortality
  Yang et al 1999^103^                   South Bay Heart Watch Cohort                                       1196             USA                     89           ≥45                 3.4                                   Incident CHD
  Yuan et al 1997^104^                   Four communities in Shanghai                                       18 244           China                   100          45--64              6.7                                   CHD and stroke mortality
  Zhang et al 2004^105^                  Northern and southern Chinese populations                          12 352           China                   100          35--59              15.2                                  Incident stroke

CHD=coronary heart disease. CVD=cardiovascular disease.

Study quality
-------------

We evaluated two primary features of study quality---the number of years that participants were followed and adjustment for confounding. Duration of follow-up for study end points ranged from 2.5 to 35 years, with a mean follow-up of 11 years (standard deviation 6 years) (table 1[](#tbl1){ref-type="table"}). Of the included studies, 13 (15%) had ≤5 years of follow-up. Similarly, studies varied in the degree of confounder adjustment, ranging from none to 18 variables, with a mean of six (SD 4). Most studies (68) presented adjusted estimates, but eight reported only unadjusted estimates and another eight adjusted only for basic demographic information. Methods of adjustment, effect measure, and confounding variables used in each study are presented in the appendix tables 1--5 on bmj.com for each of our primary outcomes.

Primary analyses of cardiovascular disease mortality, coronary heart disease incidence and mortality, and stroke incidence and mortality
----------------------------------------------------------------------------------------------------------------------------------------

For cardiovascular disease mortality and both end points for coronary heart disease, alcohol consumption was associated with lower risk, with relative risks of about 0.75 (table 2[](#tbl2){ref-type="table"}). In general, relative risks derived from the more highly adjusted and from the less adjusted results were similar. Figures 2--4[](#fig2){ref-type="fig"} [](#fig3){ref-type="fig"} [](#fig4){ref-type="fig"} reveal little visual evidence of heterogeneity despite statistical evidence of heterogeneity (P\<0.001, I^2^=72.2%), probably driven by the large number of participants (\>1 million). All the point estimates were \<1.0 in studies, except for one study for cardiovascular disease mortality and two studies for coronary heart disease incidence and mortality.

![**Fig 2** Forest plot of mortality from cardiovascular disease associated with alcohol consumption](ronp804823.f2_default){#fig2}

![**Fig 3** Forest plot of incident coronary heart disease associated with alcohol consumption](ronp804823.f3_default){#fig3}

![**Fig 4** Forest plot of mortality from coronary heart disease associated with alcohol consumption](ronp804823.f4_default){#fig4}

###### 

 Stratified analyses of pooled relative risks (95% CI) for cardiovascular and stroke outcomes (number of pooled studies in parentheses after each effect estimate)

                                            Cardiovascular disease mortality (n=21 studies, 1\<thin\>184\<thin\>956 subjects)   Coronary heart disease                                Stroke                              
  ----------------------------------------- ----------------------------------------------------------------------------------- -------------------------- -------------------------- -------- -------------------------- --------------------------
  Active drinkers *v* non-drinkers:                                                                                                                                                                                       
   Least adjusted models                    0.84 (0.75 to 0.95) (11)                                                            0.73 (0.65 to 0.82) (14)   0.80 (0.70 to 0.91) (10)            1.01 (0.88 to 1.16) (10)   1.13 (0.96 to 1.32) (3)
   Most adjusted models                     0.75 (0.70 to 0.80) (21)                                                            0.71 (0.66 to 0.77) (29)   0.75 (0.68 to 0.81) (31)            0.98 (0.91 to 1.06) (17)   1.06 (0.91 to 1.23) (10)
  Active drinkers *v* lifetime abstainers   0.82 (0.78 to 0.86) (9)                                                             0.73 (0.61 to 0.88) (9)    0.75 (0.66 to 0.85) (7)             0.93 (0.85 to 1.02) (7)    1.29 (1.09 to 1.53) (3)
  Former drinkers*v* non-drinkers           1.48 (1.23 to1.79) (6)                                                              1.10 (0.91 to 1.33) (8)    1.31 (1.02 to 1.68) (6)             0.87 (0.72 to 1.07) (4)    Not reported (2)
  Alcohol intake (g/day) *v* none:                                                                                                                                                                                        
   \<2.5                                    0.71 (0.57 to 0.89) (7)                                                             0.96 (0.86 to 1.06) (6)    0.92 (0.80 to 1.06) (6)             0.81 (0.74 to 0.89) (3)    1.00 (0.75 to 1.34) (3)
   2.5--14.9                                0.77 (0.71 to 0.83) (15)                                                            0.75 (0.65 to 0.88) (9)    0.79 (0.73 to 0.86) (18)            0.80 (0.74 to 0.87) (3)    0.86 (0.75 to 0.99) (6)
   15--29.9                                 0.75 (0.70 to 0.80) (13)                                                            0.66 (0.59 to 0.75) (15)   0.79 (0.71 to 0.88) (15)            0.92 (0.82 to 1.04) (5)    1.15 (0.86 to 1.54) (6)
   30--60                                   0.85 (0.73 to 0.98) (10)                                                            0.67 (0.56 to 0.79) (9)    0.77 (0.72 to 0.83) (12)            1.15 (0.98 to 1.35) (4)    1.10 (0.85 to 1.45) (5)
   \>60                                     0.99 (0.84 to 1.17) (6)                                                             0.76 (0.52 to 1.09) (9)    0.75 (0.63 to 0.89) (9)             1.62 (1.32 to 1.98) (4)    1.44 (0.99 to 2.10) (3)
  Sex:                                                                                                                                                                                                                    
   Men                                      0.80 (0.73 to 0.87) (13)                                                            0.71 (0.66 to 0.77) (25)   0.77 (0.72 to 0.82) (21)            1.02 (0.92 to 1.13) (11)   1.07 (0.89 to 1.28) (9)
   Women                                    0.69 (0.60 to 0.78) (9)                                                             0.71 (0.66 to 0.77) (11)   0.78 (0.64 to 0.94) (10)            0.87 (0.75 to 1.01) (4)    0.81 (0.67 to 0.98) (3)
  Adjustment for confounding factors\*:                                                                                                                                                                                   
   Weak                                     0.74 (0.67 to 0.82) (10)                                                            0.69 (0.62 to 0.76) (11)   0.72 (0.63 to 0.83) (15)            0.99 (0.86 to 1.13) (7)    1.30 (1.11 to 1.52) (5)
   Strong                                   0.76 (0.70 to 0.83) (11)                                                            0.72 (0.65 to 0.79) (18)   0.80 (0.75 to 0.86) (16)            0.99 (0.89 to 1.09) (10)   0.96 (0.81 to 1.14) (5)
  Median follow-up time†:                                                                                                                                                                                                 
   Short                                    0.76 (0.71 to 0.83) (8)                                                             0.71 (0.65 to 0.79) (14)   0.75 (0.67 to 0.85) (12)            0.98 (0.90 to 1.07) (9)    1.01 (0.82 to 1.24) (5)
   Long                                     0.75 (0.67 to 0.84) (13)                                                            0.72 (0.64 to 0.80) (15)   0.75 (0.67 to 0.84) (19)            1.00 (0.88 to 1.13) (8)    1.18 (1.02 to 1.37) (5)

\*Adjustment for confounding factors was dichotomised as weak (\<median value) or strong (≥median value). Cut points: ≥5 for coronary heart disease and stroke mortality, ≥6 for cardiovascular disease mortality and incident coronary heart disease, ≥7 for incident stroke.

†Total follow-up time was dichotomised as short (\<median value) or long (≥median value). Cut points: ≥9 for incident coronary heart disease, ≥10 for cardiovascular disease mortality, ≥12 for coronary heart disease mortality and incident stroke, ≥14 for stroke mortality.

In contrast, the overall associations of alcohol intake with stroke incidence and mortality were close to null, both in minimally adjusted and more highly adjusted models (table 2[](#tbl2){ref-type="table"}, figs 5[](#fig5){ref-type="fig"} and 6[](#fig6){ref-type="fig"}). However, this null association seemed to obscure nearly significant but opposite associations with subtypes of incident stroke. Among the 12 studies on incident haemorrhagic stroke, the pooled relative risk for current alcohol drinkers compared with non-drinkers was 1.14 (95% confidence interval 0.97 to 1.34), whereas the eight studies on ischaemic stroke showed a moderate reduction in the pooled relative risk of 0.92 (0.85 to 1.00). Alcohol use was not associated with stroke mortality, but few studies assessed the risk of mortality from haemorrhagic or ischaemic stroke separately. Furthermore, only two studies reported relative risks on stroke end points for former drinkers compared with non-drinkers.

![**Fig 5** Forest plot of incident stroke associated with alcohol consumption](ronp804823.f5_default){#fig5}

![**Fig 6** Forest plot of mortality from stroke associated with alcohol consumption](ronp804823.f6_default){#fig6}

Analyses of dose response
-------------------------

Analyses of the dose of alcohol consumed showed that 2.5--14.9 g alcohol (about ≤1 drink) per day was protective for all five outcomes compared with no alcohol (table 2[](#tbl2){ref-type="table"}). For coronary heart disease outcomes, all levels of intake \>2.5 g/day had similar degrees of risk reduction. For cardiovascular disease mortality as well as stroke incidence and mortality, the dose-response relations were less clear and more consistent with U or J shaped curves, suggesting an increased risk among drinkers of greater amounts of alcohol. Specifically, those who consumed \>60 g/day were at a significantly increased risk of incident stroke compared with abstainers (relative risk 1.62 (1.32 to 1.98)).

Sensitivity analyses
--------------------

In an analysis of differences in associations by sex, any amount of alcohol consumption relative to none was associated with greater reduction in cardiovascular disease mortality, stroke incidence, and stroke mortality for women than men. However, the association with stroke should be interpreted with caution, as the risk estimates for women are based on only three pooled studies. On the other hand, similar associations by sex were observed for coronary heart disease incidence and mortality (table 2[](#tbl2){ref-type="table"}).

Sensitivity analyses that were confined to only studies that controlled for the important confounders of smoking, age, and sex revealed generally similar results for all of the outcomes. Additional sensitivity analyses that account for the median number of confounding variables in the multivariable analyses of included studies revealed that those with fewer (less than the median) confounding variables generally reported slightly lower relative risk estimates. However, this pattern was inconsistent across the outcomes. Specifically, an increased risk of stroke mortality was observed for studies with limited adjustment for confounding. A similar trend was observed when considering the duration of follow-up. Using the pooled median number of years as the cut point, we found that studies with shorter follow-up reported a greater risk reduction for all outcomes except cardiovascular disease and coronary heart disease mortality (table 2[](#tbl2){ref-type="table"}).

Among those studies that used long term abstainers as the referent category, excluding former drinkers or evaluating them separately, the estimated association between drinking and both incidence and mortality estimates did not change substantively (table 2[](#tbl2){ref-type="table"}). Among studies that evaluated former drinkers separately, the risk of death (from cardiovascular disease and coronary heart disease) was significantly higher in former drinkers than in drinkers. However, former drinkers did not have an increased risk of incident cardiovascular events (coronary heart disease or stroke).

Finally, a sensitivity analysis that excluded the few studies where only odds ratios instead of relative risks were presented had little effect on the results. In cumulative meta-analyses of cardiovascular disease and coronary heart disease outcomes (appendix figs 1--3 on bmj.com), there was little variation in the relative risk associated with alcohol consumption on cardiovascular disease mortality or incident coronary heart disease with addition of new studies after 1999; for coronary heart disease mortality, this plateau in incremental change from new studies occurred as early as 1992--3.

Mortality from all causes
-------------------------

Of the 84 studies addressing alcohol and cardiovascular disease events, 31 also examined the association of alcohol consumption with all cause mortality. The pooled estimates from these studies showed a lower risk of all cause mortality for drinkers compared with non-drinkers (relative risk 0.87 (0.83 to 0.92)) (fig 7[](#fig7){ref-type="fig"}). However, the association was J shaped, with the lowest risk for those consuming 2.5--14.9 g/day (relative risk 0.83 (0.80 to 0.86), 16 studies) and an elevated risk in those consuming \>60 g/day (relative risk 1.30 (1.22 to 1.38), 8 studies).

![**Fig 7** Forest plot of mortality from all causes associated with alcohol consumption](ronp804823.f7_default){#fig7}

Publication bias
----------------

Visual inspection of the funnel plot for each outcome did not show asymmetry, an indication that significant publication bias was not likely. This was further confirmed by a non-significant Begg's test for each outcome (for cardiovascular disease mortality, P=0.40; incident coronary heart disease, P=0.75; coronary heart disease mortality, P=0.089; incident stroke, P=0.33; stroke mortality, P=0.59; all cause mortality, P=0.26).

Discussion
==========

In this review of 84 studies of alcohol consumption and cardiovascular disease, alcohol consumption at 2.5--14.9 g/day (about ≤1 drink a day) was consistently associated with a 14--25% reduction in the risk of all outcomes assessed compared with abstaining from alcohol. Such a reduction in risk is potentially of clinical importance, but consumption of larger amounts of alcohol was associated with higher risks for stroke incidence and mortality.

To our knowledge, this systematic review and meta-analysis is the most comprehensive to date. Although roughly similar estimates of lower risk were observed in previous meta-analyses of both coronary heart disease and stroke,[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] our review extends the findings by assessing a broader array of relevant cardiovascular outcomes and adding several new important studies. Our review clarifies several discrepancies among prior reports. Corrao et al reported a J shaped relation between alcohol intake and coronary heart disease,[@ref2] whereas the review by Maclure described this relation as L shaped because he did not observe an increase in coronary heart disease risk associated with higher alcohol consumption.[@ref6] Our updated meta-analysis supports the latter association for coronary heart disease, with a 25--35% risk reduction for light to moderate drinking[@ref106] that also is present with heavier drinking.

Our analysis of multiple cardiovascular outcomes also shows the complexities inherent in the study of alcohol consumption. Modest alcohol intake was associated with lower stroke incidence and mortality, but the risk increased substantially with heavier drinking (that is, a J shaped relation). Furthermore, the association of alcohol consumption is complex and differs by stroke subtype, with a slightly lower risk of ischaemic stroke but higher risk of haemorrhagic stroke. These differential associations probably reflect the known antithrombotic effects of alcohol.[@ref107] Alcohol consumption, particularly at high doses, also seems to have an adverse association with blood pressure that may account, in part, for the higher risk of haemorrhagic stroke associated with heavier drinking.[@ref108] Additionally, our analysis does not consider other known detrimental effects of high alcohol consumption.[@ref3] Therefore, our findings lend further support for limits on alcohol consumption.[@ref106] [@ref109]

Our review also highlights other important aspects of the relation between alcohol consumption and cardiovascular disease. Firstly, the lower risk of coronary heart disease associated with alcohol consumption was at least as strong for women as for men. Limited evidence suggests that the risk of stroke related to alcohol is lower for women than men, but this may only reflect lower alcohol intake among women. Secondly, inclusion of former drinkers did not seem to bias the association of alcohol consumption with cardiovascular disease. Thirdly, when studies were summarised chronologically, we found that the overall association between drinking and cardiovascular disease and coronary heart disease became apparent at least a decade ago, and ongoing studies have done little to revise the estimated associations.

An argument for causation
-------------------------

From the extensive body of literature summarised here, the association between alcohol consumption and decreased cardiovascular risk is not in question, as additional research has not changed this conclusion. Rather, the lingering question is whether this association is causal. Clearly, observational studies cannot establish causation. However, when the present results are coupled with those from our companion review paper summarising interventional mechanistic studies focusing on biomarkers associated with cardiovascular disease,[@ref110] the argument for causation becomes more compelling. Indeed, the mechanistic biomarker review shows biological plausibility for a causal association by showing favourable changes in pathophysiologically relevant molecules.

Therefore, we can now examine the argument for causation based on Hill's criteria.[@ref111] Beyond the biological plausibility argument discussed above, there is an appropriate temporal relation with alcohol use preventing cardiovascular disease. Secondly, we have observed a greater protective association with increasing dose, except that it seems to be offset somewhat by negative associations with the risk of haemorrhagic stroke. Thirdly, the protective association of alcohol has been consistently observed in diverse patient populations and in both women and men. Fourthly, the association is specific: moderate drinking (up to 1 drink or 12.5 g alcohol per day for women and 2 drinks or 25 g alcohol per day for men[@ref106]) is associated with lower rates of cardiovascular disease but is not uniformly protective for other conditions, such as cancer.[@ref112] Lastly, the reduction in risk is notable even when controlling for known confounders (such as smoking, diet, and exercise). Any potential unmeasured confounder would need to be very strong to explain away the apparently protective association.

Limitations of study
--------------------

The results of our meta-analysis should be interpreted in context of the limitations of available data. Firstly, the quality of individual studies varied, with some studies having limited follow-up and limited adjustment for potential confounding. With respect to study follow-up, it is possible that misclassification of alcohol consumption may increase with study length because of changes in drinking habits over time. It is also possible that potential biological effects of alcohol vary with time of exposure. However, arguing against both these possibilities, the analysis stratified by length of follow-up did not show different associations between alcohol intake and outcome for shorter follow-up times versus longer times.

Secondly, only a limited subset of studies provided specific risk estimates for different beverages. Although there is great interest in differences between beer, wine, and spirits, alcoholic drinks generally have similar effects on high density lipoprotein cholesterol,[@ref113] and it is likely that any particular benefit of wine is prone to confounding by diet and socioeconomic status.[@ref114] [@ref115] None the less, this remains an interesting topic for further investigation.

Thirdly, we found only limited information on the relation between alcohol intake and mortality from subtypes of stroke, so this topic continues to be important for large observational cohort studies. Finally, we observed significant heterogeneity across studies for several of our pooled analyses. This may be due in great part to large study sample sizes, which can confer greater statistical power to heterogeneity tests, whereas the clinical relevance of this heterogeneity may be quite modest.[@ref10] Visual inspection of our various forest plots and the relative consistency of pooled relative risks across clinical and methodological variables suggest that there is considerable consistency in the relative risk findings across studies and across strata.

Implications
------------

Given the consistency observed in our findings and compelling mechanistic data pointing to causation in our companion review, additional observational studies will have limited value except to elucidate more precisely the association of alcohol and stroke.[@ref116] Rather, debate should centre now on how to integrate this evidence into clinical practice and public health messages. In the realm of clinical practice, the evidence could form a foundation for proposing counselling for selected patients to incorporate moderate amounts of alcohol into their diets to improve their coronary heart disease risk. However, such a clinical strategy requires formal evaluation in pragmatic clinical trials that assess the questions of optimal patient selection, compliance, risks, and benefits. The focus of such trials would shift from assessing the association between alcohol and disease outcomes to evaluating the receptivity of both physicians and patients to the recommended consumption of alcohol for therapeutic purposes and the extent to which it can be successfully and safely implemented. In support of implementation trials, our two papers show that alcohol consumption in moderation has reproducible and plausible effects on markers of coronary heart disease risk.

With respect to public health messages, there may now be an impetus to better communicate to the public that alcohol, in moderation, may have overall health benefits that outweigh the risks in selected subsets of patients. Again, any such strategy would need to be accompanied by rigorous study and oversight of impacts. One approach would be to undertake public health messaging pilot studies on well defined target populations (such as a workplace or in a small jurisdiction) to permit detailed evaluation of effects on measures such as knowledge, attitudes, self reported drinking behaviours, and perhaps, secondarily, health outcomes.

The debate on how to integrate this evidence into clinical practice and public health messages will require integration of all possible effects of alcohol---from injury and violence to glucose metabolism and inflammation---and recognition that these effects may be distributed unequally across the population. For example, injury risk probably disproportionately affects younger individuals, whereas cardiovascular disease mainly affects older adults. Robust studies that examine multiple outcomes simultaneously are needed to identify those subsets of the population in which reduced cardiovascular risk might dominate against those for whom the risks of social and medical problems (including several cancers and injury[@ref112] [@ref117]) are too great. Despite the latter concerns, results of our secondary analysis of overall mortality (fig 5[](#fig5){ref-type="fig"}) support the notion that moderate alcohol consumption is associated with net benefit, at least in populations similar to those studied in the extant literature.

Our two systematic review papers summarise a surprisingly extensive body of literature on the relation between alcohol and cardiovascular disease. Our findings point to the need to define implications for clinical and public health practice. These reviews and the perspectives above provide a foundation for that dialogue.

### What is already known on this topic:

1.  Systematic reviews have addressed the association of alcohol consumption with various cardiovascular outcomes

2.  However, these reviews are somewhat out of date, and none has comprehensively studied a broad spectrum of relevant cardiovascular end points

### What this study adds

1.  This meta-analysis provides a summary of current knowledge regarding alcohol associations with six meaningful clinical end points---cardiovascular disease mortality, coronary heart disease incidence and mortality, stroke incidence and mortality, and all cause mortality

2.  The results confirm the beneficial effects of moderate alcohol consumption and the need to elucidate the underlying pathophysiological mechanisms

Preliminary results from this manuscript were presented at the 32nd annual meeting of the Society of General Internal Medicine, Miami, Florida, 14 May 2009.
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